Weight loss injectables like Ozempic have gained popularity in Bengaluru, with patients sourcing them from abroad. The ...

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 71 trades. If we consider the specifics of each ...

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide. “We feel that a product like an oral, orforglipron, could serve a significant ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive — and covered an exclusive trip for leaders to attend last summer’s ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

The weight loss potential is not exactly there to match the likes of Eli Lilly’s tirzepatide or Novo Nordisk’s CagriSema which has an amylin analog as a “performance enhancer” on top of ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other low risk stocks. Risk is a key consideration in investing and portfolio management ...

Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily ...

March 12 (Reuters) - U.S. drugmakers Johnson & Johnson (JNJ.N), opens new tab and Eli Lilly (LLY.N), opens new tab increased spending on security for their top executives in 2024, citing increased ...